Background. Radical resection is the primary treatment for rectal cancer. When anastomosis is possible, a temporary ileostomy is used to decrease morbidity from a poorly healed anastomosis. However, ileostomies are associated with complications, dehydration, and need for a second operation. We sought to evaluate the impact of ileostomyrelated complications on the treatment of rectal cancer. Methods. We conducted a retrospective study of patients who underwent sphincter-preserving surgery between January 2005 and December 2010 at a tertiary cancer center. The primary outcome was the overall rate of ileostomy-related complications. Secondary outcomes included complications related to ileostomy status, ileostomy closure, anastomotic complications at primary resection, rate of stoma closure, and completion of adjuvant chemotherapy assessed by multivariate logistic regression. Results. Of 294 patients analyzed, 32 % (n = 95) were women. Two hundred seventy-one (92 %) received neoadjuvant chemoradiation. The median tumor distance from the anal verge was 7 cm (interquartile range 5-10 cm). Two hundred eighty-one (96 %) underwent stoma closure at a median of 7 months (interquartile range 5.4-8.3 months). The most common complication related to readmission was dehydration (n = 32-11 %). Readmission within 60 days of primary resection was associated with delay in initiating adjuvant chemotherapy (odds ratio 3.01, 95 % confidence interval 1.42-6.38, p = 0.004). Conclusions. Diverting ileostomies created during surgical treatment of rectal cancers are associated with morbidity; however, this is balanced against the risk of anastomosis-related morbidity at rectal resection. Given the potential benefit of fecal diversion, patient-oriented interventions to improve ostomy management, particularly during adjuvant chemotherapy, can be expected to yield marked benefits.
INTRODUCTION
Anastomotic leakage is one of the most significant complications after resection with anastomosis for rectal cancer. Although temporary ileostomies may decrease morbidity associated with anastomotic leaks, they are not risk free. A recent retrospective review of 603 patients with diverting ileostomies identified a 16.9 % readmission rate within 60 days postoperatively, with dehydration being the most common cause. 1 In addition, a prospective cohort study demonstrated that all patients with diverting ileostomies had a significant decrease in their glomerular filtration rates measured just before ileostomy closure compared to just after ileostomy creation. 2 Other ileostomy-related complications such as small bowel obstruction, stoma necrosis, prolapse, or retraction may not only result in readmissions but may also require reoperation. Other less clinically serious complications such as leakage from the stoma appliance and skin irritation may lead to a decrease in the patient's quality of life.
Patients with temporary ileostomies are also at risk for complications associated with a second operation for ileostomy closure. A systematic review of over 6,000 patients reported an overall morbidity associated with ileostomy closure of 17.3 %. 3 Moreover, although the diverting ileostomy is meant to be temporary, not all patients receive closure; the incidence of a permanent stoma has been reported to be as high as 20 %. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Although much has been published regarding complications associated with ileostomies, data regarding the impact of ileostomies on the multidisciplinary care of the rectal cancer patient are lacking.
The purpose of this study was to evaluate the prevalence of ileostomy-related complications during treatment of rectal cancer at a comprehensive cancer center and to describe its impact on multidisciplinary care.
MATERIALS AND METHODS
An institutional review board approved retrospective analysis of prospectively collected data supplemented by chart review was conducted of patients treated for rectal cancer with sphincter preservation from January 2005 to December 2010 at MD Anderson Cancer Center in Houston, Texas. All patients who underwent rectal resection with anastomosis and received a planned diverting ileostomy were included. Patients with recurrent rectal tumors, synchronous tumors, nonadenocarcinomatous rectal masses, or multivisceral resections were excluded. Diverting ileostomies were used in all patients who received rectal resection with anastomosis after neoadjuvant therapy and in the absence of neoadjuvant therapy at the discretion of the operating surgeon. Before ileostomy closure, all patients underwent routine imaging of the anastomotic area with Gastrografin enema and some also had direct endoluminal visualization of the anastomosis. At the time of stoma closure, patients either had closure of skin with staples, closure over a Penrose drain, closure with wicks, or loose interrupted primary closure.
Data were collected regarding baseline demographics, tumor characteristics, operative techniques, and complications associated with primary surgery, stoma closure, and the interval period. Anastomotic leak was defined as any of the following: extravasation of contrast from the anastomosis, presence of a pelvic fluid collection requiring antibiotic therapy with or without percutaneous drainage, signs of peritonitis, or leakage of pus or feces from a pelvic drain. Placement of pelvic drains at the time of primary resection was based on surgeon discretion. Comorbidities were defined using the Charlson-Deyo classification system. 17 Patients were classified according to the World Health Organization definition of obesity if their body mass index was C30 kg/m 2 . Ileostomy-related complications were separated into two categories: complications related to having an ileostomy (or ileostomy status) and complications of ileostomy closure. Complications of ileostomy status included readmission for dehydration and need for stoma revision. Other outcomes that were evaluated included delayed initiation of adjuvant therapy ([8 weeks after primary resection), failure to complete adjuvant therapy (receiving less than 3 months), and stoma-related problems (e.g., bleeding, prolapse). Additionally, we collected data regarding complications at primary resection (e.g., anastomotic leak) in order to determine the impact of the ileostomy on primary surgery-related complications. Surgical site infections were defined using the Centers for Disease Control and Prevention definitions. 18 Statistical analyses were performed by Stata 12 software (College Station, TX). Student's t test was used to evaluate continuous variables, and logistic regression was performed to evaluate categorical variables.
RESULTS
There were a total of 372 patients who underwent rectal resections with anastomosis and ileostomy during the given time period. Of those, 294 patients met our inclusion criteria. Baseline demographic data are presented in Table 1 . Most tumors were located in the mid or distal rectum, and more than two-thirds of the patients were male. The majority of the patients received neoadjuvant therapy. The median length of stay after resection with anastomosis was 6 days (interquartile range [IQR] 5-8). The median length of follow-up was 44.5 months (IQR 29-63). The description of operative approaches is described in Table 2 .
Interval Complications of Ileostomy Status
There were 63 patients (21 %) with 75 readmissions within 60 days after primary resection before stoma closure (Fig. 1) . The most common reason for readmission was dehydration (35 readmissions in 32 patients), and 53 % (n = 17) of those patients had at least a 50 % increase in their creatinine levels at readmission compared to their preoperative values (Table 3) . Median initial length of stay (days, IQR) after primary resection was not significantly greater in those who were readmitted within 60 days compared to those who were not (6, 5-9 vs. 6, 5-8, p = 0.62). As shown in Fig. 1 , among those with no readmissions, 7 % (16 of 231) had a delay in adjuvant therapy. The rate of delay among those with readmission within 60 days and a stoma-related complication was 30 % (12 of 40), more than quadruple that of the no-readmissions group. Although we cannot make causal claims on the basis of retrospective data, the observed number of patients with a delay in the readmissions group far exceeds the expected number based on those with no readmission.
Complications at Ileostomy Closure
Two hundred eighty-one (96 %) patients eventually underwent stoma closure at a median of 7 months (IQR 5.4-8.3) after primary tumor resection. The median length of stay (days) at the time of closure was 4 (IQR 3-5). Eleven patients (4 %) required laparotomy for closure of the ileostomy. The most common complications were ileus (n = 31, 11 %), followed by surgical site infection (n = 23, 8.2 %) and small bowel obstruction (n = 10, 5.6 %). Five patients (1.8 %) required subsequent colostomy as a result of bowel dysfunction (increased frequency, increased urgency, anorectal pain, perianal excoriation, inability to completely evacuate). The most common wound-related reason for late readmission ([60 days) was herniorrhaphy (parastomal n = 18, ventral n = 12).
Impact on Adjuvant Chemotherapy
Two hundred sixty-six patients (90.5 %) received some adjuvant chemotherapy with 191 (65 %) completing at least 3 months. There were 37 (12.5 %) patients who had a delay in starting adjuvant chemotherapy (adjuvant therapy initiated [8 weeks after primary resection). Readmission within 60 days was significantly associated with delay in initiating adjuvant chemotherapy (odds ratio [OR] 3.01, 95 % confidence interval [CI] 1.42-6.38, p = 0.004). In fact, one in three readmitted patients incurred a delay, and the most common reasons for readmissions were stoma related (63 %, n = 40). Surgical site infections were the cause of readmission in 9 (14 %) and itself did not reach statistical significance as a predictor of delay (OR 1.98, 95 % CI 0.95-4.12, p = 0.07). Thirty-three patients (13 %) had 40 readmissions during their course of adjuvant chemotherapy. There were 36 patients (14 %) who did not complete at least 3 months of adjuvant chemotherapy; however, patients with stoma-related complications were all ultimately able to initiate adjuvant therapy.
Complications at Primary Resection
Data regarding complications at primary resection were also collected to evaluate the impact of the ileostomy on primary tumor resection-related complications (Table 4) . A total of 86 patients (28 %) had some type of wound-related infectious complication. After primary resection, there LAR low anterior resection, uLAR ultralow anterior resection were 41 (13.9 %) patients with anastomotic leak or pelvic abscess, 16 (39 %) of which were asymptomatic leaks identified only on routine imaging before ileostomy closure. Of those with asymptomatic leaks, two (12.5 %) were managed with percutaneous drainage, one (6.3 %) required reoperation, and 15 (93.4 %) had stoma closure. Of the 25 with symptomatic leaks, six (24 %) required reoperation and 14 (56 %) were managed with percutaneous drainage. Male gender was associated with increased risk of anastomotic leak or pelvic abscess (OR 3.9, 95 % CI 1.5-10.3, p = 0.006). Obesity (body mass index C30 kg/m 2 ) was significantly associated with development of superficial surgical site infection (OR 2.5, 95 % CI 1.34-4.72, p = 0.004). The median length of stay (days, IQR) was significantly greater for patients who had any surgical site infection compared to those who did not (7, 6-9 vs. 6, 5-7, p \ 0.001). Furthermore, having any type of surgical site infection was associated with readmission within 60 days (OR 2.14, 95 % CI 1.15-3.98, p = 0.016).
DISCUSSION
In this study we evaluated the impact of diverting ileostomies on the multidisciplinary treatment of rectal cancer and observed that stoma-related complications were a major factor with respect to delays in adjuvant chemotherapy initiation. However, although the risk for ileostomy-related morbidity was remarkable, in this population of primarily irradiated low rectal cancer patients, fecal diversion was also associated with approximately 40 % of anastomosis-related complications being asymptomatic, and identified only during routine radiographic interrogation before ileostomy reversal. In addition, those patients whose leaks were clinically apparent could typically be managed by relatively low-risk interventions such as percutaneous intervention. These findings suggest that fecal diversion with ileostomy plays an important role in rectal cancer management but additional interventions should be directed at reducing the risk for ileostomy-related morbidity.
In addition to anastomotic complications, this study also evaluated wound-related complications at primary tumor resection and ileostomy reversal. The relatively high rate of superficial surgical site infections at primary resection was unexpected. Among patients who underwent minimally invasive resections, further investigation demonstrated that infectious complications were often associated with the wound in proximity to the ileostomy. In fact among patients who underwent laparoscopy and developed a surgical site infection, at least half were manifest as erythema at the right lateral port site (adjacent to ileostomy). Together the wound and ileostomy-related complications impacted the receipt of adjuvant chemotherapy primarily associated with a delay to initiation. Although this observation approached statistical significance in this study (p = 0.07), it is likely that a larger sample size would have demonstrated a more clear effect. This is a particular concern as delaying initiation of adjuvant chemotherapy by more than 2 months in stage III colon cancer patients is associated with a higher mortality. 19 A retrospective review of stage II and III rectal cancer patients using the Surveillance, Epidemiology, and End Results database used postoperative hospital stay as a surrogate for postoperative complications and found it to be an independent predictor for delay in beginning adjuvant chemotherapy. 20 We found that readmission within 60 days after primary resection was significantly associated with delay in initiation of adjuvant chemotherapy. Because dehydration was the most common reason for readmission, preventing readmissions due to dehydration should be an important priority.
Because there is evidence that diverting ileostomies decrease complications relating to anastomotic leak after rectal resection, it is important to evaluate the ways in which ileostomy-related morbidity may be reduced. [21] [22] [23] Our findings of risk for dehydration and need for readmission and impact on renal function are consistent with prior reports from diverse reporting centers demonstrating that the challenges are universal and still need further study.
1,2 Perhaps the greatest opportunity for improvement is through interventions to manage the volume of ileostomy output. There are existing guidelines and algorithms regarding treatment of high output stomas. 24, 25 For example, one algorithm for treatment of high-output stomas (greater than 2,000 ml/24 h for 3 or more consecutive days) is broken into 3 stages: (1) identify causes of high output (sepsis, SBO, medications, infectious colitis, etc.); (2) progression through use of medications to decrease output; and (3) intravenous fluids to rehydrate the patient. Unfortunately, this algorithm is geared toward treating patients who are already symptomatic, have been admitted, and have been referred to the hospital's nutrition support team; earlier intervention would be better. Another obstacle to more widespread use of protocols for treatment of high output stomas is the varying definition of what constitutes high output, which ranges from 1,000 ml/24 h to more than 2,000 ml/24 h. 26, 27 Establishing a clinically meaningful definition of high output may be an important first step toward identifying patients most at risk for dehydration and designing interventions to prevent and identify dehydration before it progresses to require hospital intervention. Although some advocate early closure of the ileostomy, enthusiasm for this must be balanced against the need to have sufficient time to allow both primary colorectal anastomosis and ileostomy closure-related enteroenterostomy to heal before initiation of adjuvant chemotherapy. This is especially important in light of fact that increasing the time to adjuvant chemotherapy initiation may decrease its benefit.
There are several limitations to this study. First, this was a retrospective review at a comprehensive cancer center that draws patients from around the world. In our study 33 % of patients were either from another state or from another country. Therefore, this may underrepresent stoma-related complications that occur at home or at outside hospitals. In addition, we defined dehydration as having been admitted for ostomy-related dehydration, and we were therefore not able to measure the impact of ostomy-related complications that did not require readmission. This was a single-center review, which may limit the generalizability of the findings. For example, the median age of the cohort was 56.2 yearsyounger than expected from the general population. An older cohort may have been subject to a higher risk for some stoma-related complications such as dehydration. However, factors such as immediate complications and their effect on initiation and completion of adjuvant therapy are universal and generalizable. Data regarding adverse effects of chemotherapy were not recorded, and could not be accounted for as a reason for delay. Finally, in this study we did not evaluate long-term outcomes data, so the effects of readmission, delays in adjuvant chemotherapy, and ileostomyrelated morbidity on recurrence and survival cannot be determined at this time. Diverting ileostomies created during surgical treatment of rectal cancers are associated with a significant risk for ileostomy-related morbidity including dehydration and perioperative complications of stoma closure. However, this morbidity may be balanced by the benefit of decreasing anastomosis-related morbidity at rectal resection. Given the potential benefit of fecal diversion, future studies of patient-oriented interventions to improve stoma management, particularly during adjuvant chemotherapy could improve overall outcomes.
